Editor’s note: One in a series of articles on managing cancer-related symptoms from the Oncology Nursing Society.
Basic cognitive abilities are measured by attention and concentration, executive function, information processing speed, language, visuospatial skills, psychomotor ability, learning, and memory (Jansen, Miaskowski, Dodd, Dowling, & Kramer, 2005). Cognitive impairment, then, is defined by Allen (2011) as a decline in function of one or many of these domains. Unfortunately, many cancer diagnoses or their treatments can lead to cognitive impairment for patients—a distressing side effect and one that may continue to afflict patients after treatment has ended.
The incidence of cognitive impairment varies by type of cancer, type of treatment, and time since diagnosis (Allen, 2011). Early studies on cognitive impairment focused on patients with brain tumors and, interestingly, found that 50% to 80% of these patients have cognitive impairment at the time of diagnosis (Tucha, Smely, Preier, & Lange, 2000). This suggested that the impairment was mainly caused by the tumor itself. More recent studies have concluded that cognitive impairment is present in other populations of patients with cancer prior to treatment: 11% to 35% of patients with breast cancer, 70% to 80% of patients with lung cancer, and 40% of patients with acute myeloid leukemia (Ahles et al., 2007; Hermelink et al., 2007; Hurria et al., 2006; Meyers, Albitar, & Este, 2005; Meyers, Byrne, & Komaki, 1995). And, as mentioned earlier, additional research has found that 20% to 30% of cancer survivors experience significant cognitive impairment after treatment has ended (Vardy, Wefel, Ahles, Tannock, & Schagen, 2007; Von Ah et al., 2009). Survivors experiencing this symptom often report subtle declines in memory, concentration, and executive functioning (Allen, 2011), which may lead to difficulties at home and work.
Because of the amount of interaction oncology nurses have with their patients, they are in a unique position to recognize cognitive changes in those patients. Surveys and clinician-administered tests are available (see Subjective instruments used to measure cognitive impairment), but many require special training to administer. A detailed assessment of patient self-reports of problems, such as forgetfulness, difficulty with memory, and difficulty with multitasking, can be helpful in determining potentially treatable causes and to determine if symptoms are worsening over time (Allen, 2011). If so, oncology nurses should refer patients to a neuropsychologist for additional evaluation (Allen, 2011).
Subjective instruments used to measure cognitive impairment
Tool Name: Attentional Function Index
Number of Items: 13
Characteristics: For patients with breast or lung cancer. The tool focuses on attention, executive function, and working memory. Adequate reliability and validity have been established.
Tool Name: Cognitive Failures Questionnaire
Number of Items: 25
Characteristics: For patients with breast cancer or gliomas. The tool focuses on perception, memory, and attention. Adequate reliability has been established.
Tool Name: Functional Assessment of Cancer Therapy—Cognitive
Number of Items: 50
Characteristics: Various types of cancers are targeted, including breast, multiple myeloma, non-Hodgkin lymphoma, and prostate. The tool focuses on mental acuity, concentration, verbal and nonverbal memory, and verbal fluency. Adequate reliability and validity have been established.
Tool Name: Patient’s Assessment of Own Functioning
Number of Items: 33
Characteristics: For patients with breast cancer. The tool focuses on memory, executive function, language and communication, and sensory-perceptual and motor skills. Sufficient reliability and validity have been established.
Tool Name: Perception of Cognition Questionnaire
Number of Items: 7
Characteristics: For patients with breast cancer. The tool focuses on attention and concentration, executive function, memory, and language. Limited reliability and validity.
Note. Adapted with permission from Allen (2011).
Putting Evidence Into Practice
To promote nursing practice that is based on evidence, the Oncology Nursing Society (ONS) launched the Putting Evidence Into Practice (PEP) program in 2005. ONS PEP teams consisting of advanced practice nurses, staff nurses, and a nurse scientist were charged with reviewing the literature to determine what treatments and interventions are proven to alleviate many cancer-related problems that are sensitive to nursing interventions. Each team classified interventions under the following categories: recommended for practice, likely to be effective, benefits balanced with harms, effectiveness not established, effectiveness unlikely, not recommended for practice, and expert opinion.
However, to date, there are no evidence-based preventive measures for cognitive impairment caused by cancer or cancer treatment. Possible interventions are classified as effectiveness not established and will be identified here.
Effectiveness not established
These items have insufficient or conflicting data or data of inadequate quality with no clear indication of harm.
Methylphenidate is a psychostimulant that was found to improve cognitive function in adults with cancer in studies by Bruera, Miller, Macmillan, and Kuehn (1992), Gagnon, Low, and Schreier (2005), and Meyers, Weitzner, Valentine, and Levin (1998). However, three more recent randomized, controlled trials failed to demonstrate significant improvement in cognitive functioning in patients who were given methylphenidate (Butler et al., 2007; Lower et al., 2009; Mar Fan et al., 2008). Additional research is needed.
Studies also have been conducted with donepezil and modafinil with similar mixed results. Of the two trials conducted with donepezil, Shaw et al. (2006) reported some improvement in cognitive functioning; however, simultaneous improvements in tumor size may have confounded the results. The second trial (Jatoi et al., 2005) failed to find a significant effect of donepezil and vitamin E on cognitive function. With modafinil, all three studies (Blackwell, Petroni, Shu, Baum, & Farace, 2009; Kohli et al., 2009; Lundorff, Jonsson, & Sjøgren, 2009) reported improvement in some aspects of cognitive performance, but differed on which aspects. Additional randomized, controlled trials are needed to determine efficacy (Allen et al., 2011).
Complementary and alternative therapies
The impact of exercise on cognitive impairment was studied in two nonrandomized trials. Schwartz, Thompson, and Masood (2002) combined four months of exercise with the administration of methylphenidate and recorded improvements in visual attention, motor speed, and cognitive flexibility. Korstjens, Mesters, van der Peet, Gijsen, and van den Borne (2006) noted improvements in cognitive function after 3 months of an exercise program coupled with an educational program on fatigue. However, cognitive function was measured by self-report with no objective measurements used. Further replication with comparison groups and objective measures is needed for this promising intervention (Allen et al., 2011).
Vitamin E received mixed results from two separate trials. Chan, Cheung, Law, and Chan (2004) administered 1,000 international units of vitamin E twice daily for 1 year and recorded improvements in global cognition, verbal and visual memory, and executive function. However, Jatoi et al. (2005) failed to find a significant effect when patients were given 5 mg per day of donepezil and 1,000 international units per day of vitamin E for 3 months. Differences in study design and time of these two studies was noteworthy (Allen et al., 2011).
Cognitive training program interventions
Several studies explored the use of cognitive training programs to improve cognitive impairment in patients with cancer. These programs varied in design, personnel, involvement with caregivers, and duration (Allen et al., 2011), and consisted of computer-based programs (Ferguson et al., 2007; Gehring et al., 2009; Poppelreuter, Weis, & Bartsch, 2009) or sessions with trained healthcare professionals (Locke et al., 2008; McDougall, 2001; Sherer, Meyers, & Bergloff, 1997). All of the programs offered concurrent psychoeducational training. And, while all appeared to have positive results, many of the studies were limited by small sample sizes and a lack of a comparison group (Allen et al., 2011).
Areas for research
Allen et al. (2011) determined focused areas of needed research to address cognitive impairment in patients with cancer. Researchers should aim to understand the prevalence and trajectory of cognitive impairment across various types of cancers and their treatments and identify potential predictors of cognitive impairments so that patients at risk may be treated sooner. In addition, assessment tools that are reliable, valid, sensitive to subtle changes, and easily conducted in a clinical setting are needed. Research should strive to identify the underlying physiologic mechanism associated with cognitive impairment and to identify symptoms of cognitive impairment (e.g., pain, sleep disturbance, fatigue, depression) that may hinder effective treatment. Together, results from these research items may lead to effective evidence-based interventions to treat patients suffering from cognitive impairment.
Sean Pieszak is a staff editor in the Publications department at the Oncology Nursing Society (ONS) in Pittsburgh, Pennsylvania. More information about the ONS Putting Evidence into Practice classification for cognitive impairment can be found at http://www.ons.org/Research/PEP/cognitive.
Ahles, T.A., Saykin, A.J., McDonald, B.C., Furstenberg, C.T., Cole, B.F., Hanscom, B.S., . . . Kaufman, P.A. (2007). Cognitive function in breast cancer patients prior to adjuvant treatment. Cancer Research and Treatment, 110, 143–152.
Allen, D.H. (2011). Cognitive impairment. In L.H. Eaton, J.M. Tipton, & M. Irwin (Eds.), Putting Evidence into Practice: Improving oncology patient outcomes (vol. 2, pp. 15–22). Pittsburgh, PA: Oncology Nursing Society.
Allen, D.H., Von Ah, D., Jansen, C., Schiavone, R.M., Gagnon, P., Wulff, J., & Behrendt, R. (2011). Cognitive impairment. In L.H. Eaton, J.M. Tipton, & M. Irwin (Eds.), Putting Evidence into Practice: Improving oncology patient outcomes (vol. 2, pp. 23–30). Pittsburgh, PA: Oncology Nursing Society.
Blackwell, L., Petroni, G., Shu, J., Baum, L., & Farace, E. (2009). A pilot study evaluating the safety and efficacy of modafinil for cancer-related fatigue. Journal of Palliative Medicine, 12, 433–439. doi:10.1089/jpm.2008.0230
Bruera, E., Miller, M.J., Macmillan, K., & Kuehn, N. (1992). Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain, 48, 163–166.
Butler, J.M., Jr., Case, L.D., Atkins, J., Frizzell, B., Sanders, G., Griffin, P., . . . Shaw, E.G. (2007). A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. International Journal of Radiation Oncology, Biology, Physics, 69, 1496–1501. doi:10.1016/j.ijrobp.2007.05.076
Chan, A.S., Cheung, M.C., Law, S.C., & Chan, J.H. (2004). Phase II study of alpha-tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer, 100, 398–401.
Ferguson, R.J., Ahles, T.A., Saykin, A.J., McDonald, B.C., Furstenberg, C.T., Cole, B.F., & Mott, L.A. (2007). Cognitive-behavioral management of chemotherapy-related cognitive change. Psycho-Oncology, 16, 772–777. doi:10.1002/pon.1133
Gagnon, B., Low, G., & Schreier, G. (2005). Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: A prospective clinical study. Journal of Psychiatry Neuroscience, 30, 100–107.
Gehring, K., Sitskoorn, M.M., Gundy, C.M., Sikkes, S.A.M., Klein, M., Postma, T. J., . . . Aaronson, N.K. (2009). Cognitive rehabilitation in patients with gliomas: A randomized, controlled trial. Journal of Clinical Oncology, 27, 3712–3722. doi:10.1200/JCO.2008.20.5765
Hermelink, K., Untch, M., Lux, M.P., Kreienberg, R., Beck, T., Bauerfeind, I., & Munzel, K. (2007). Cognitive function during neoadjuvant chemotherapy for breast cancer: Results of a prospective, multicenter, longitudinal study. Cancer, 109, 1905–1913.
Hurria, A., Rosen, C., Hudis, C., Zuckerman, E., Panageas, K.S., Lachs, M.S., . . . Holland, J. (2006). Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study. Journal of the American Geriatrics Society, 54, 926–931.
Jansen, C.E., Miaskowski, C.A., Dodd, M.J., Dowling, G.A., & Kramer, J. (2005). Potential mechanisms for chemotherapy-induced impairments in cognitive function. Oncology Nursing Forum, 32, 1151–1163. doi:10.1188/04.ONF.1151-1163
Jatoi, A., Kahanic, S.P., Frytak, S., Schaefer, P., Foote, R.L., Sloan, J., & Petersen, R.C. (2005). Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: Preliminary results and suggestions for future study designs. Support Care Center, 13, 66–69. doi: 10.1007/s00520-004-0696-0
Kohli, S., Fisher, S.G., Tra, Y., Adams, M.J., Mapstone, M.E., Wesnes, K.A., . . . Morrow, G.R. (2009). The effects of modafinil on cognitive function in breast cancer survivors. Cancer, 115, 2605–2616. doi:10.1002/cncr.24287
Korstjens, I., Mesters, I., van der Peet, E., Gijsen, B., & van den Borne, B. (2006). Quality of life of cancer survivors after physical and psychosocial rehabilitation. European Journal of Cancer Prevention, 15, 541–547. doi:10.1097/01.cej.0000220625.77857.95
Locke, D.E., Cerhan, J.H., Wu, W., Malec, J.F., Clark, M.M., Rummans, T.A., & Brown, P.D. (2008). Cognitive rehabilitation and problem-solving to improve quality of life of patients with primary brain tumors: A pilot study. Journal of Supportive Oncology, 6, 383–391.
Lower, E. E., Fleishman, S., Cooper, A., Zeldis, J., Faleck, H., Yu, Z., & Manning, D. (2009). Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: A randomized clinical trial. Journal of Pain and Symptom Management, 38, 650–662. doi:10.1016/j.jpainsymman.2009.03.011
Lundorff, L.E., Jonsson, B.H., & Sjøgren, P. (2009). Modafinil for attentional and psychomotor dysfunction in advanced cancer: A double-blind randomised, cross-over trial. Palliative Medicine, 23, 731–738. doi:10.1177/0269216309106872
Mar Fan, H.G., Clemons, M., Xu, W., Chemerynsky, I., Breunis, H., Braganza, S., & Tannock, I.F. (2008). A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Center, 16, 577–583. doi:10.1007/s00520-007-0341-9
McDougall, G.J., Jr. (2001). Memory improvement program for elderly cancer survivors. Geriatric Nursing, 22, 185–190. doi:10.1067/mgn.2001.117916
Meyers, C.A., Albitar, M., & Este, E. (2005). Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or Myelodysplastic syndrome. Cancer, 104, 788–793.
Meyers, C.A., Weitzner, M.A., Valentine, A.D., & Levin, V.A. (1998). Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. Journal of Clinical Oncology, 16, 2522–2527.
Poppelreuter, M., Weis, J., & Bartsch, H.H. (2009). Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. Journal of Psychosocial Oncology, 27, 274–296. doi:10.1080/07347330902776044
Schwartz, A.L., Thompson, J.A., & Masood, N. (2002). Interferon-induced fatigue in patients with melanoma: A pilot study of exercise and methylphenidate [Online exclusive]. Oncology Nursing Forum, 29, E85–E90. doi:10.1188/02.ONF.E85-E90
Shaw, E.G., Rosdhal, R., D’Agostino, R.B., Lovato, J. Naughton, M.J., Robbins, M.E., & Rapp, S.R. (2006). Phase II study of donepezil in irradiated brain tumor patients: Effect on cognitive function, mood, and quality of life. Journal of Clinical Oncology, 24, 1415–1420. doi:10.1200/JCO.2005.03.3001
Sherer, M., Meyers, C.A., & Bergloff, P. (1997). Efficacy of postacute brain injury rehabilitation for patients with primary malignant brain tumors. Cancer, 80, 250–257. doi:10.1002/(SICI)1097-0142(19970715)80:23.0.CO;2-T
Tucha, O., Smely, C., Preier, M., & Lange, K.W. (2000). Cognitive deficits before treatment among patients with brain tumors. Neurosurgery, 47, 324–333.
Vardy, J., Wefel, J.S., Ahles, T., Tannock, I.F., & Schagen, S.B. (2007). Cancer and cancer-therapy related cognitive dysfunction: An international perspective from the Venice cognitive workshop. Annals of Oncology, 19, 623–629.
Von Ah, D., Harvison, K.W., Monahan, P.O., Moser, L.R., Zhao, Q., Carpenter, J.S., . . . Unverzagt, F.W. (2009). Cognitive function in breast cancer survivors compared to healthy age- and education-matched women. Clinical Neuropsychologist, 23, 661–674.